Literature DB >> 31902593

Race and socioeconomic differences associated with endovascular peripheral vascular interventions for newly diagnosed claudication.

Caitlin W Hicks1, Peiqi Wang2, William E Bruhn2, Christopher J Abularrage3, Ying W Lum3, Bruce A Perler3, James H Black3, Martin A Makary4.   

Abstract

BACKGROUND: Despite guidelines cautioning against the use of endovascular peripheral vascular interventions (PVI) for claudication, more than 1.3 million PVI procedures are performed annually in the United States. We aimed to describe national rates of PVI for claudication, and identify patient and county-level risk factors associated with a high rate of PVI.
METHODS: We used the Medicare claims database to identify all Medicare beneficiaries with a new diagnosis of claudication between January 2015 and June 2017. A hierarchical logistic regression model accounting for patient age, sex, comorbidities; county region and setting; and a patient race-county median income interaction was used to assess the associations of race and income with a high PVI rate.
RESULTS: We identified 1,201,234 patients with a new diagnosis of claudication for analysis. Of these, 15,227 (1.27%) underwent a PVI. Based on hierarchical logistic regression accounting for patient and county-level factors, black patients residing in low-income counties had a significantly higher odds of undergoing PVI than their white counterparts (odds ratio [OR], 1.30; 95% confidence interval [CI], 1.20-1.40), whereas the odds of PVI for black versus white patients was similar in high-income counties (OR, 1.06; 95% CI, 0.99-1.14). PVI rates were higher for low versus high-income counties in both the black (OR, 1.46; 95% CI, 1.31-1.64) and white (OR, 1.19; 95% CI, 1.12-1.27) groups. There were no significant associations of Hispanic, Asian, North American native, or other races with PVI in either low- or high-income counties after risk adjustment (all P ≥ .09).
CONCLUSIONS: In the Medicare population, the mean rate of PVI of 12.7 per 1000 claudication patients varies significantly based on race and income. Our data suggest there are racial and socioeconomic differences in the treatment of claudication across the United States.
Copyright © 2019 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Claudication; Disparities; Medicare; Peripheral artery disease; Race; Socioeconomic status

Mesh:

Year:  2020        PMID: 31902593      PMCID: PMC7731457          DOI: 10.1016/j.jvs.2019.10.075

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  37 in total

1.  Preoperative medical testing in Medicare patients undergoing cataract surgery.

Authors:  Catherine L Chen; Grace A Lin; Naomi S Bardach; Theodore H Clay; W John Boscardin; Adrian W Gelb; Mervyn Maze; Michael A Gropper; R Adams Dudley
Journal:  N Engl J Med       Date:  2015-04-16       Impact factor: 91.245

2.  National trends in lower extremity bypass surgery, endovascular interventions, and major amputations.

Authors:  Philip P Goodney; Adam W Beck; Jan Nagle; H Gilbert Welch; Robert M Zwolak
Journal:  J Vasc Surg       Date:  2009-05-28       Impact factor: 4.268

3.  Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Sanjay Rajagopalan; Santo Dellegrottaglie; Anna L Furniss; Brenda W Gillespie; Sudtida Satayathum; Norbert Lameire; Akira Saito; Takashi Akiba; Michel Jadoul; Nancy Ginsberg; Marcia Keen; Friedrich K Port; Debabrata Mukherjee; Rajiv Saran
Journal:  Circulation       Date:  2006-10-23       Impact factor: 29.690

4.  Sex differences in claudication pain in subjects with peripheral arterial disease.

Authors:  Andrew W Gardner
Journal:  Med Sci Sports Exerc       Date:  2002-11       Impact factor: 5.411

5.  Socioeconomic and ethnic disparities in cardiovascular risk in the United States, 2001-2006.

Authors:  Arun S Karlamangla; Sharon Stein Merkin; Eileen M Crimmins; Teresa E Seeman
Journal:  Ann Epidemiol       Date:  2010-08       Impact factor: 3.797

6.  Adapting the Elixhauser comorbidity index for cancer patients.

Authors:  Hemalkumar B Mehta; Sneha D Sura; Deepak Adhikari; Clark R Andersen; Stephen B Williams; Anthony J Senagore; Yong-Fang Kuo; James S Goodwin
Journal:  Cancer       Date:  2018-02-01       Impact factor: 6.860

7.  Prevalence of symptomatic and asymptomatic peripheral arterial disease and the value of the ankle-brachial index to stratify cardiovascular risk.

Authors:  R Ramos; M Quesada; P Solanas; I Subirana; J Sala; J Vila; R Masiá; C Cerezo; R Elosua; M Grau; F Cordón; D Juvinyà; M Fitó; M Isabel Covas; A Clarà; M Angel Muñoz; J Marrugat
Journal:  Eur J Vasc Endovasc Surg       Date:  2009-06-10       Impact factor: 7.069

8.  Gender and peripheral arterial disease.

Authors:  Tracie C Collins; Maria Suarez-Almazor; Ruth L Bush; Nancy J Petersen
Journal:  J Am Board Fam Med       Date:  2006 Mar-Apr       Impact factor: 2.657

9.  Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis.

Authors:  A W Gardner; E T Poehlman
Journal:  JAMA       Date:  1995-09-27       Impact factor: 56.272

10.  Peripheral Artery Disease Prevalence and Incidence Estimated From Both Outpatient and Inpatient Settings Among Medicare Fee-for-Service Beneficiaries in the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Corey A Kalbaugh; Anna Kucharska-Newton; Lisa Wruck; Jennifer L Lund; Elizabeth Selvin; Kunihiro Matsushita; Lindsay G S Bengtson; Gerardo Heiss; Laura Loehr
Journal:  J Am Heart Assoc       Date:  2017-05-03       Impact factor: 5.501

View more
  1 in total

1.  Risk of peripheral artery disease according to race and sex: The Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Caitlin W Hicks; Ning Ding; Lucia Kwak; Shoshana H Ballew; Corey A Kalbaugh; Aaron R Folsom; Gerardo Heiss; Josef Coresh; James H Black; Elizabeth Selvin; Kunihiro Matsushita
Journal:  Atherosclerosis       Date:  2021-03-29       Impact factor: 5.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.